Horizon Pharma price target raised to $18 from $16 at JMP Securities JMP Securities increased its price target on Horizon as the firm reports that the company's Vimovo drug is outpacing the firm's early expectations. The firm thinks the company could increase its 2014 guidance on its upcoming Q4 earnings call. JMP Securities expects the stock to rise following the earnings, and recommends owning the shares ahead of the results. It reiterates an Outperform rating on the shares.
Horizon Pharma announces notice of allowance with claims covering Ravicti Horizon Pharma announced that it has received from the United States Patent and Trademark Office a Notice of Allowance for U.S. patent application number 13/775,000, entitled "Methods of Therapeutic Monitoring of Nitrogen Scavenging Drugs" that covers Horizon's U.S. approved product Ravicti Oral Liquid.